Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery libraries including both (1) highly diverse synthetic naïve antibody phage display libraries and (2) target class specific antibody phage display libraries against difficult-to-drug targets.  In this talk, Aaron Sato, CSO, will present on how Twist uses our libraries coupled with Machine Learning to discover 1) antibody sequences from NGS sequencing of our successive panning rounds and 2) optimize existing leads derived from traditional screening.

CAR-T 细胞疗法是一种富有前景的实体瘤治疗方法。但要确定专门针对肿瘤抗原的适当 T 细胞受体（TCR）结构域依然是一个挑战。Toxicity, tumor activation, and tumor persistence are significant challenges to using CAR-T cell therapies for solid tumors.In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept studies showing how these technologies can be utilized for cell therapies. Aaron will also be joined by Justin Farlow, CTO of Serotiny, who will tell the story of how Twist’s Combinatorial Assembly Libraries helped his company design and evaluate thousands of CARs, each with novel intracellular signaling architectures. 通过使用这些文库，Serotiny 快速地选择了多种新颖的 CAR 设计，进而增强原代 T 细胞的治疗性能。

Twist synthetic DNA technologies have enabled the development of precision antibody libraries designed to bind to G protein-coupled receptors (GPCRs). We have employed high throughput binding and functional assays to discover antibodies with agonist and antagonist profiles. This parallel functional screening was successfully employed for discovery of novel therapeutic antibody ligands for three GPCRs (called GLP1R, APJR and C5AR1). Twist synthetic DNA technologies allow for the design of novel antibody-based GPCR ligands with profiles for clinical therapeutic development.